WARRINGTON, Pa., May 14, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), announces the publication of results from its previously-conducted Phase 2a feasibility study of Aerosurf®, the Company’s aerosolized KL4 surfactant, for the prevention of respiratory distress syndrome (RDS) in premature infants, in the May 2010 issue of the Journal of Aerosol Medicine and Pulmonary Drug Delivery in the study titled “An Open Label, Pilot Study of Aerosurf® Combined with nCPAP to Prevent RDS in Preterm Neonates” (Finer et al., Journal of Aerosol Medicine and Pulmonary Drug Delivery 2010).
